PHENOMENAL

orange__line

Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study).

Multicenter open-label, phase II trial, to Evaluate the Efficacy and Safety of nal-IRI in patients with HER2-negative breast cancer, who have documented Central Nervous System (CNS) progression following Whole Brain Radio Therapy (WBRT), Stereotactic Radiosurgery (SRS) and/or surgery, as determined by the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.

NAME TUMOR TYPE TITLE PHASE N SITES COUNTRY STATUS
PHENOMENAL
Her2-negative MBC Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer II 26 18 Spain Actively enrolling patients

AACR 2018 – Download the abstract